Search Results - "Schilling, William H.K."
-
1
The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis
Published in Journal of antimicrobial chemotherapy (02-05-2024)“…Effective antiviral drugs accelerate viral clearance in acute COVID-19 infections; the relationship between accelerating viral clearance and reducing severe…”
Get full text
Journal Article -
2
Does hydroxychloroquine still have any role in the COVID-19 pandemic?
Published in Expert opinion on pharmacotherapy (03-07-2021)“…: The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years for malaria and rheumatological conditions, respectively. Their…”
Get more information
Journal Article -
3
No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency
Published in Blood cells, molecules, & diseases (01-11-2020)Get full text
Journal Article -
4
Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger
Published in The American journal of tropical medicine and hygiene (06-09-2023)“…In 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a rapidly emerging virus causing the coronavirus disease 2019 (COVID-19) pandemic, had…”
Get full text
Journal Article -
5
Blood culture negative endocarditis in the modern era of 16S rRNA sequencing
Published in Clinical medicine (London, England) (01-07-2020)“…Blood culture negative endocarditis (BCNE) accounts for up to 20% of infective endocarditis. While the most common cause of BCNE remains the initiation of…”
Get full text
Journal Article -
6
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Published in The Lancet infectious diseases (01-01-2024)“…Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their antiviral activities in patients have not…”
Get full text
Journal Article -
7
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Published in The Journal of infectious diseases (15-11-2023)“…Abstract Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus disease 2019 (COVID-19) has resulted in varying treatment…”
Get full text
Journal Article -
8
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Published in The Lancet infectious diseases (01-09-2024)“…Effective antiviral drugs prevent hospitalisation and death from COVID-19. Antiviral efficacy can be efficiently assessed in vivo by measuring rates of…”
Get full text
Journal Article -
9
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Published in BMC infectious diseases (15-01-2024)“…In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance. Favipiravir, an anti-influenza drug, has in vitro…”
Get full text
Journal Article -
10
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
Published in eLife (21-02-2023)“…There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a…”
Get full text
Journal Article -
11
Cutaneous stigmata associated with insulin resistance and increased cardiovascular risk
Published in International journal of dermatology (01-09-2014)“…Certain cutaneous conditions have been reported to be associated with diabetes mellitus, insulin resistance, and metabolic syndrome. In this novel review…”
Get full text
Journal Article -
12
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Published in Wellcome open research (2021)“…The World Health Organization living guideline on drugs to prevent COVID-19 has recently advised that ongoing trials evaluating hydroxychloroquine in…”
Get full text
Journal Article -
13
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Published in Wellcome open research (2021)“…In rural areas of South and Southeast Asia malaria is declining but febrile illnesses still account for substantial morbidity and mortality. Village health…”
Get full text
Journal Article -
14
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)
Published in Wellcome open research (15-10-2020)“…There is no proven preventative therapy or vaccine against COVID-19. Theinfection has spread rapidly and there has already been a substantial adverse impact on…”
Get full text
Journal Article -
15
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Published in Wellcome open research (01-01-2021)“…In rural areas of South and Southeast Asia malaria is declining but febrile illnesses still account for substantial morbidity and mortality. Village health…”
Get full text
Journal Article